The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.

  • End date
    Oct 28, 2022
  • participants needed
  • sponsor
    Incyte Corporation
Updated on 24 November 2021


Safety and tolerability of monotherapy or combination in patients that have participated in a previous parent study to treat advanced malignancies.


A Phase 2 Open-Label, Multicenter, Rollover Study to evaluate the long term safety and tolerability of Pemigatinib and to provide Continued Treatment for Participants With Advanced Malignancies Previously Enrolled in Studies of Pemigatinib

Condition Advanced Malignancies
Treatment Pembrolizumab, pemigatinib, Retifanlimab
Clinical Study IdentifierNCT04949191
SponsorIncyte Corporation
Last Modified on24 November 2021


Yes No Not Sure

Inclusion Criteria

Currently enrolled and receiving treatment in an Incyte-sponsored clinical study (parent protocol) of pemigatinib as monotherapy or combination therapy
Currently benefiting from and tolerating treatment with pemigatinib, as determined by the investigator
Demonstrated compliance, as assessed by the investigator, with the parent protocol requirements
Willingness and ability to comply with scheduled visits, treatment plans, and any other study procedures
Currently have no evidence of progressive disease, as determined by the investigator, following treatment with pemigatinib as monotherapy or combination therapy
Willingness to avoid pregnancy or fathering children

Exclusion Criteria

Able to access pemigatinib commercially or outside of a clinical trial
Permanently discontinued from the parent protocol for any reason
No longer meet the inclusion/exclusion criteria from the parent protocol if still receiving treatment
Women who are pregnant or breastfeeding or participants expecting to conceive or father children within the projected duration of the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note